Development and Validation of a Nomogram Model for Prognostic Assessment in Primary Cervical Squamous Cell Carcinoma with Serum SCC Antigen Levels ≥10 ng/mL Using Inflammatory Biomarkers and Clinical Variables - Takeaways - MDSpire

Development and Validation of a Nomogram Model for Prognostic Assessment in Primary Cervical Squamous Cell Carcinoma with Serum SCC Antigen Levels ≥10 ng/mL Using Inflammatory Biomarkers and Clinical Variables

  • By

  • Yiwei Zhao

  • Chutong Zhao

  • Yujie Liu

  • Yuan Wang

  • Yunyan Zhang

  • Sijia Liu

  • March 7, 2026

  • 0 min

Share

  • 1

    Cervical cancer is the most common malignancy in women, primarily caused by persistent HPV infection.

  • 2

    Patients with pretreatment SCC-Ag levels ≥10 ng/mL have a higher likelihood of recurrence and poorer survival outcomes.

  • 3

    The study aims to develop a prognostic model integrating inflammatory markers and clinical variables for patients with high SCC-Ag.

  • 4

    A total of 355 patients with primary cervical cancer and high SCC-Ag levels were retrospectively enrolled for model development.

  • 5

    The model's validation involved an independent cohort to assess its predictive performance for personalized treatment strategies.

Original Source(s)

Development and Validation of a Nomogram Model for Prognostic Assessment in Primary Cervical Squamous Cell Carcinoma with Serum SCC Antigen Levels ≥10 ng/mL Using Inflammatory Biomarkers and Clinical Variables

  • by Yiwei Zhao, Chutong Zhao, Yujie Liu, Yuan Wang, Yunyan Zhang, Sijia Liu

  • March 7, 2026

Related Content

Frameless linac-based radiosurgery for benign intracranial tumors treated with HyperArc: analysis of tumor control and toxicity

Recurrent meningioma treated with boron neutron capture therapy: a feasibility study with dosimetric and clinical correlates

The dynamic nature of frailty in metastatic spine disease patients